Venclose Announces Closing of Series B Financing
July 11, 2018—Venclose, Inc., a developer of solutions for the treatment of venous reflux disease, announced the closing of the Series B round of financing that will be used to support new product development as well as expansion of manufacturing capabilities and general corporate purposes.
The company is commercializing its Venclose radiofrequency (RF) ablation system, which is designed to close damaged veins and restore healthy blood flow in patients with venous reflux disease. The Venclose RF system is available in the United States and Europe.
Venclose also announced that Jeffrey G. Carr, MD, has joined the company as Chief Medical Officer.